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Abstract
Background: Dendritic cells (DC) play the key role in directing antigen-specific immune
responses and manipulating their function may be a useful tool for immunotherapy. The balance
between immune stimulation and tolerance is particularly important at mucosal interfaces, where
discrimination between dangerous pathogens and innocuous antigens takes place. In humans,
although much is known about the responses of monocyte derived DC, relatively little is known
about effect of immuno-stimulatory adjuvants on DC found in tonsil.
Results: To examine this, tonsil DC were isolated and cultured with potent DC activators; IFNγ,
anti-CD40 antibody, LPS and Poly I:C either singly or in combination. To measure maturation and
activation, DC were examined for changes in the expression of HLA-DR, HLA- class I, CD83,
CD40, CD80 and CD86 and the release of IL12p70.
The DC isolated from tonsil were a mixed population containing both myeloid and plasmacytoid
DC, but all showed similar responses. Tonsil DC released IL12p70 upon stimulation with IFNγ ,
anti-CD40 antibody, and LPS, but unlike monocyte-derived DC, they did not increase the
expression of cell surface activation molecules above those induced by culture alone. Poly I:C, a
potent stimulator of laboratory generated DC inhibited the activation of tonsil DC by other
adjuvants.
Conclusion: As the response of this mixed population of DC does not mirror that of DC
generated in vitro, this may have implications for other tissue residing DC and might be an important
consideration for immunotherapy.
Background
Dendritic cells orchestrate the primary antigen specific
immune response and manipulating their function could
potentially benefit the treatment of many disorders
including autoimmune diseases and cancers. Their pri-
mary function is to present antigen to naïve T lym-
phocytes and in so doing either induce or suppress the
immune response. Induction occurs if antigen is recog-
nised as potentially dangerous. This requires a second sig-
nal, such as pro-inflammatory cytokines, CD40-CD40L
signalling or prostaglandins [1-3]. The DC respond to
these signals by upregulating the cell-surface molecules
required for efficient antigen presentation and naïve T
lymphocyte activation (HLA class I, HLA-DR, CD80,
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cytokines, such as IL-12 [4,5]. Antigen presentation in the
absence of second signals causes anergy or unrespon-
sivenes [6-8]. Suppression of the immune response may
also be achieved by the action of different subsets of DC
including plasmacytoid DC or by the interaction of regu-
latory T cells with DC [9-12]. The outcome of antigen
presentation therefore depends upon the subsets of cells
and accessory signals that are present in the tissue micro-
environment.
Much of our knowledge of human DC has been gained
through the study of monocyte or bone marrow derived
DC generated and manipulated in vitro (MoDC) [13].
Monocytes cultured in the presence of IL-4 and GMCSF
differentiate into immature myeloid DC, characterised by
high expression of HLA-DR and CD11C. Subsequently, a
variety of adjuvants can be used to induce DC maturation
and activation. Various adjuvants have been tested on cul-
tures of MoDC to varying effect, but the most potent
described include bacterial lipopolysaccharide (LPS),
recombinant nucleotides that mimic viral infection (Poly
I:C), CD40/CD40L interactions and the cytokine IFNγ
[14-17].
To the contrary, data presenting activation of human tis-
sue-derived DC, i.e. gut or respiratory tract, are very scarce
and little is know how they respond to direct activation
with immuno-adjuvants. Nevertheless, tissue DC have
long been recognized as the key regulators of immune
responses [18-22] and understanding of their biology may
significantly improve management of immune related
disorders as well as cancer. To investigate the response of
tissue-derived DC, we created an alternative to MoDC
model, using palatine tonsils, which have long been a
source of human lymphoid tissue.
Tonsils protect the gateway of both respiratory and ali-
mentary tract and their main function is to discriminate
between potentially infectious pathogens and innocuous
airborne and food antigens. They are particularly interest-
ing because they are constitutively immunosuppressed as
part of the mucosa-associated lymphoid tissue (MALT),
but are still able to evoke a potent immune response to
pathogens [22,23]. A number of DC subsets have been
identified in tonsil. Like all DC they express HLA-DR in
the absence of the lineage associated markers CD3, CD19,
CD14 & CD16 but are distinguishable by the intensity of
HLA-DR and the expression of CD11C & CD123 [24,25].
The HLA-DR+, CD11C+ subset generated from mono-
cytes can also be identified in tonsil but it is not known if
both populations function similarly.
To examine whether tonsil DC respond to adjuvant acti-
vation in a similar manner to laboratory generated DC we
have isolated DC from tonsil and cultured them with a
number of immune adjuvants commonly used to activate
monocyte derived DC, including some which could be
used therapeutically in cancer. Our results show that
mixed DC populations from tonsil can be activated with
adjuvants but that their responses do not directly correlate
with those of monocyte-derived DC. In particular, Poly
I:C appears to suppress activation and IL-12 release in
response to potent adjuvant stimuli.
Results
Isolation of Tonsil DC
The techniques developed for the isolation of tonsil DC
allowed us to recover reasonable numbers of viable cells
relatively quickly. A total of 15 tonsils were investigated.
The original cell suspension contained on average 1.68 ±
0.40 × 109 cells in total. The purification process removed
T and B lymphocytes, tonsil stromal cells and red blood
cells and resulted in a fraction containing 8 × 104 to 1 ×
107 cells, mean 2.68 ± 0.69 × 106. The final cell popula-
tion was highly enriched in DC. CD19, CD3 and CD14
positive cells were rare (< 0.5%). Up to 96.5% of the puri-
fied cells were HLA-DR+ (mean: 65.1% ± 6.64), and
expressed CD11c (30.63% ± 4.12), CD123 (37.1% ±
5.46), CD83 (5.15% ± 0.44). Cells positive for both HLA-
DR and CD11c (myeloid DC) accounted for 16.3 ± 3.55%
of the purified APC fraction (Table 1). A typical example
of the enriched DC fraction is shown in Figure 1. The FSC
and SSC profiles show the size and granularity of the
events and were used to position the live cell region (R1,
Fig. 1a). Dead cells and cell debris are shown above and
to the left of R1. This scatter profile shows the wide varia-
tion in size of the cells in the purified fraction. There are
two main mutually exclusive populations defined by
expression of either CD11C or CD123 and HLA-DR (Fig.
1b, d) neither of which express high levels of CD83 (Fig.
1c). The HLA-DR negative cells in the fraction are proba-
bly contaminating macrophages.
We next examined the phenotype of the tonsil DC fraction
in terms of the DC activation markers: CD40, CD80,
CD83, CD86 and HLA DR. As the tonsil fraction was het-
erogeneous and included immature myeloid DC
(CD11c+/HLA-DRmed), plasmacytoid DC (CD123+) and
activated DC (CD11c+/HLA DRhi), described by Hart and
colleagues (21), we compared the expression of DC acti-
vation markers on the whole fraction and on CD11c+/
HLA DRhi cells (Fig. 2). Compared to the whole fraction,
the CD11c+/HLA-DRhi DC express slightly more of each of
the activation markers.
Culture of tonsil DC with adjuvant
We next cultured the tonsil DC fraction with a range of
commonly used adjuvants previously shown to activate
monocyte derived DC. These included IFNγ, a humanizedPage 2 of 12
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The expression of DC markers on the tonsil DC fractionFigure 1
The expression of DC markers on the tonsil DC fraction. The DC fraction from tonsil was investigated for expression 
of the DC markers: CD11c (myeloid DC), CD123 (plasmacytoid DC) and CD83 (mature DC). A representative example is 
shown. The FSC, SSC profile (A) shows the size and granularity of the events and was used to set a region (R1) around the via-
ble cells. This excluded dead cells, debris and any contaminating large stromal cells from the analysis. The percentages shown 
are the percentage of cells within R1 that fall into the quadrants.
BMC Immunology 2008, 9:10 http://www.biomedcentral.com/1471-2172/9/10monoclonal antibody against CD40 that mimics T cell
interactions via CD40 ligand, GMCSF, bacterial LPS, and
Poly I:C. To assess their effect we measured IL-12, a pro-
inflammatory cytokine secreted by mature DC. IL-12p70,
the bioactive subunit of IL-12, was measured after 36–48
hours using the ELISpot technique in tonsil DC from 5
individuals. Unstimulated cells cultured in medium alone
produced low amounts of IL-12, while both anti-CD40
antibody and IFNγ proved to be strong activators of tonsil
DC (Fig. 3a). The combination of anti-CD40 antibody
and IFNγ increased IL-12 to levels seen using INFγ alone
indicating this cytokine to be particularly potent. The
addition of LPS alone did not affect IL-12 production but
the combinations of LPS and anti-CD40 antibody or LPS
and IFNγ induced unexpectedly high numbers of DC to
produce IL-12 (Fig. 3b). The highest levels of IL-12 release
were achieved when all three adjuvants were combined
(Figure 3b). Sequences of nucleotides rich in cytosine and
guanine have been shown to be very potent activators of
monocyte-derived DC (16). However, when Poly I:C was
added to tonsil DC it greatly antagonised the release of IL-
12 induced by any other immune-adjuvant, and even
depressed the baseline production of IL-12 in cell culture
(Fig. 3c). This was not due to the death of the DC as both
microscopic examination and propidium iodide/annexin
V studies failed to show any evidence of apoptosis or
excessive loss of viability using poly I:C (data not shown).
Changes in antigen expression
Activated DC express increased amounts of antigen pre-
senting molecules and co-stimulatory molecules on their
surface that facilitate efficient lymphocyte activation. We
therefore examined the changes in surface antigen expres-
sion on tonsil and monocyte derived DC following cul-
ture with adjuvants. In order to compare the CD11c+/
HLA DRhi activated DC these were gated during the data
analyses. (Figure 4 a–d). Compared to monocyte derived
DC, tonsil CD11c+/HLA DRhi DC showed a less marked
response to the adjuvants investigated. The culture of ton-
sil DC in media alone induced an up-regulation of CD86,
HLA DR, HLA class I (Fig. 4b). The response to the most
potent combination of adjuvants CD40, IFNγ & LPS is
shown in Fig. 4c. From this it is clear that although there
is some up-regulation of class I and CD86 it is not very
dramatic and does not reach the same levels as those seen
on monocyte derived DC (Fig. 4e). The combination of
anti-CD40 antibody and IFNγ (data not shown) had very
little effect over and above culture in medium alone. As
observed for IL-12 production, Poly I:C suppressed tonsil
DC activation in culture, in particular decreasing the
expression of CD86 (Fig. 4d). This effect was observed to
an even greater extent when the whole population of ton-
sil APC was examined (data not shown). Poly I:C also
caused some cell shrinkage and we observed depletion of
CD123+, HLA class hi cells (data not shown). These results
were consistent for all 10 tonsils analysed.
As a control, we investigated the responses of monocyte
derived DC obtained from peripheral blood. After the
standard 5 days in culture with GMCSF and IL4, the
monocytes differentiated into DC, expressing HLA class I
hi, HLA DRhi & CD11C. The CD11c+/HLA DR hi cells com-
prised up to 80% of the cultures. These DC were then
either cultured with the same immune-adjuvants as tonsil
DC, left in culture with GMCSF and IL4, or transferred to
culture medium for two consecutive days. We did not
observe any difference between an extra 48 hours in
GMCSF and IL4 over culture in media alone: the expres-
sion of CD86 increased under both conditions (data not
shown). Culture of the cells in the triple adjuvant combi-
nation; anti-CD40, IFNγ & poly I:C up-regulated HLA-
class I, HLA-DR and CD86 over and above the levels seen
in tonsil DC (Fig. 4c &4e). Interestingly, unlike tonsil, the
addition of poly I:C did not cause a dramatic decrease in
any of these markers (Fig. 4f)
As plasmacytoid DC make up a proportion of the tonsil
DC population we also examined the changes in expres-
sion of activation molecules by CD123+/HLA DRhi cells
after stimulation. Figure 5 illustrates the changes in
expression of CD86 after culture with anti-CD40 IFNγ &
LPS and the effect of poly I:C. Once again the adjuvant
combination increased CD86 expression and poly I:C
antagonised this. We did not observe any correlation
between the initial proportion of each DC sub-population
and the ultimate effect of the adjuvants.
Discussion
Most knowledge of the biology of DC has been acquired
from studies of monocyte or blood precursor derived DC,
generated and matured in vitro. However, the biology of
DC residing in tissues may be more complex, because of
the presence of several subsets of DC and interactions
with the microenvironment. In particular, DC residing in
mucosal interfaces are exposed to immuno-suppressive
micro-environment, and both their phenotype and their
responses to immune adjuvants may be different. In this
Table 1: Phenotype of APC freshly isolated from tonsils.
Dendritic cell marker Positive cell fraction [%]
CD11c 30.63 ± 4.12 (11.96–63.51)
CD123 37.10 ± 5.46 (15.94–52.94)
CD83 5.15 ± 0.44 (4.04–5.72)
HLADR 65.10 ± 6.64 (32.15–96.46)
HLADRhigh and CD11c+ 16.3 ± 3.55 (10.94–28.37)
The numbers in the table show the mean percentage value of positive 
fraction from all 15 tonsils analysed, with the SEM value. The values in 
brackets show the range of values for each subset analyzed.Page 4 of 12
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tion and immune-activation in short-term cultures.
Tonsil APC, depleted of T and B lymphocytes, consist of
monocytes, macrophages, and several subsets of myeloid
and plasmacytoid DC. We compared the phenotype and
responsiveness of the CD11c+/HLA DRhi sub-population
from tonsil, the characteristic phenotype of activated mye-
loid DC and blood monocyte-derived DC. We found that
the differences between these two populations were con-
The expression of DC activation markers on DCFigure 2
The expression of DC activation markers on DC. Whole tonsil DC (I) and the CD11c+/HLA DRhi tonsil DC (II) and 
monocyte-derived DC (III) were compared for the expression of HLA-Class I (B), HLA-DR (C), CD80 (D), CD83 (E) and 
CD86 (F). R1 represents the region used to gate the cells of interest (A); MFI (mean fluorescence intensity); MFI M1 (mean flu-
orescence intensity in marker 1).Page 5 of 12
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The production of IL-12 from tonsil DC after stimulation with immune-adjuvantsFigure 3
The production of IL-12 from tonsil DC after stimulation with immune-adjuvants. Tonsil APC were stimulated 
with CD40L, IFNγ, LPS and Poly IC either singly (a) or in combinations with LPS (b) or Poly I:C (c). Production of IL12 by 
unstimulated cells in culture (M0) was measured for comparison. The grey bars show adjuvants and adjuvant combinations 
alone and the black show these same adjuvants or combinations together with LPS (b) or Poly I-C (c) The bars represent mean 
values of three wells from one representative experiment of five, ± SEM.
BMC Immunology 2008, 9:10 http://www.biomedcentral.com/1471-2172/9/10siderable, and that fresh tonsil DC have a suppressed phe-
notype compared to freshly-generated monocyte-derived
DC. Tissue-residing DC are supposed to be immature,
nevertheless the expression of DC activation markers
(HLA class I, HLADR, CD40, CD80, CD86), on the surface
of tonsil CD11c+/HLA DRhi was distinguishably weak in
comparison with laboratory-generated DC. In addition,
CD123+ plasmacytoid DC made up a significant fraction
in the total tonsil DC population. The culture of tonsil DC
in media alone induced some activation perhaps reversing
immunosuppression of tonsil DC by their microenviron-
ment, although it is also possible that the isolation proce-
dure and culture conditions had some effect. Tonsil DC
and blood monocyte-derived DC responded differently to
the immune adjuvants, CD40L, IFNγ, LPS and Poly IC,
each of which are potent immune stimuli for monocyte
derived DC. These stimuli induce both a significant
increase in the expression of surface antigens necessary for
antigen presentation (surface expression of HLA class I
and HLA-DR as well as co-stimulatory molecules CD80
and CD86) and production of IL12p70.
Changes in DC surface antigen expression after stimulation with immune-adjuvantsFigur  4
Changes in DC surface antigen expression after stimulation with immune-adjuvants. CD11c+/HLA DRhi tonsil DC 
(a-d) and blood monocyte-derived DC (e-f) were investigated by flow cytometry before stimulation (a), after overnight culture 
in medium alone (b) and after culture with anti-CD40, IFNγ and LPS (c & e) or anti-CD40, IFNγ, LPS and Poly I:C (d & f). The 
isotype control was used to set the marker M1. The MFI of the cells in MI is shown on the left. The data shown comes from 
one representative experiment of ten performed.Page 7 of 12
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Changes in expression of CD86 on tonsil plasmacytoid DCFigur  5
Changes in expression of CD86 on tonsil plasmacytoid DC. CD123+/HLADRhi plasmacytoid DC were gated during 
analysis (a). Marker M1 was set using an isotype control on unactivated cells (b). CD86 was examined after activation with anti-
CD40 and IFNγ (c) anti-CD40, IFNγ and LPS (d) anti-CD40, IFNγ, LPS and Poly I:C (e). The numbers in right upper corners 
show MFI values for region M1. The data shown comes from one representative experiment of three performed.
BMC Immunology 2008, 9:10 http://www.biomedcentral.com/1471-2172/9/10Despite the significant proportion of myeloid DC in the
tonsil DC fraction, none of the adjuvants used in our
study, or the most powerful combination of them,
resulted in the high levels of antigen presenting and co-
stimulatory molecules seen using monocyte derived DC.
Since the total tonsil DC population and plasmacytoid
CD123+ DC reacted similarly to the CD11c+/HLA DRhi
DC, we suggest that the relative unresponsiveness is not a
direct result of modulation by an immunosuppressed
subset of DC but an intrinsic feature of cells residing in
peripheral tonsil. Little is known about interactions
between different subsets of DC, although some evidence
exists for the enhancement of antigen stimulation by an
interplay between plasmacytoid and myeloid DC in
autoimmune diseases and HIV infections [26,27], but to
our knowledge the down-regulation of antigen presenting
abilities of myeloid DC by a tolerogenic subset has not
been demonstrated, and this area requires further investi-
gation.
In contrast to the phenotypic data, adjuvant activation did
induce some secretion of IL12p70, as measured by ELIS-
pot. In accordance with previous studies of DC from
blood and tissues by other laboratories, we found that
LPS, anti-CD40 antibody and IFNγ induced expression of
IL12p70, both alone and in combination. Although LPS
did not greatly promote DC activation on its own, it acted
synergistically with anti-CD40 antibody. Stimulation of
CD40 by CD40L was reported as the most potent DC
stimulus for IL12 production, with IFNγ as a strong co-
stimulatory signal [2]. In this study, IFNγ was the most
potent single inducer of IL12 p70, and this was unaffected
by anti-CD40 antibody. This may suggest the existence of
an IL12 induction pathway that is independent of CD40
signalling.
One unexpected finding was that Poly I:C inhibited the
maturation and activation of tonsil DC, both in terms of
IL12p70 secretion and surface antigen expression. The
suppressive effect of Poly I:C was similar whether it was
used as a single agent or in combination with other stim-
uli, even with the most potent combination of anti-CD40
antibody, IFNγ and LPS. This contradicts the belief that
IFNγ stimulation cannot be reversed [28]. It should be
noted that Poly I:C was reported to be a potent inducer of
inflammatory cytokine expression in pure myeloid DC,
generated in a laboratory, but the tonsil DC in this study
were a mixed population, predominantly myeloid and
plasmacytoid DC. In this case, Poly I:C not only reversed
the stimulation achieved by other agents, it acted as inhib-
itory molecule per se. A similar finding was recently
reported by others in murine models of autoimmune dis-
orders [29-31]. The main Poly I:C transduction pathway,
TLR3/TLR4 activation of IkkE, leads to the maturation of
blood precursor derived "myeloid-like" DC. Poly I:C can
act however via intracellular mechanisms omitting TLR
[32]. In myeloid DC the TLR-induced production of
inflammatory cytokines is entirely mediated by MyD88
[32] and it is therefore unlikely that Poly I:C influences
this process. The interaction of dsRNA and plasmacytoid
DC is usually not considered to occur as they lack the
TLR3 on their surface [33]; but the possibility that Poly I:C
acts in a TLR3-independent manner cannot be excluded.
Another possibility is that Poly I:C is too potent an activa-
tor of inflammatory responses, and its ability to mature
DC is susceptible to crossover effects from other regula-
tory mechanisms. Genes such as IRAK-M, SOCS-1,
MyD88s, SIGGIRR and ST2 modulate TLR evoked
responses, and SOCS-1 directly down-modulates TLR sig-
nalling pathways, especially in response to LPS [32]. Con-
trol by these genes is exerted mainly by negative feedback,
so that strong stimulation by Poly I:C would result in
silencing of gene expression. Since Poly I:C shares path-
ways with LPS and possibly with IFNγ, it could reverse
their effect by pathway "overloading". It does not affect
the CD40 pathway, until NFkB is activated late in the TLR-
mediated intracellular pathway [32].
Poly I:C has been used in a number of studies as a potent
inducer of DC maturation to assisting the activation of T
lymphocytes and has even been tested in clinical trials
[13,15,16,34]. Our study shows, however, that when
applied to tonsil DC, Poly I:C silences the immune
response instead of eliciting it. This finding might be
important for DC treatment strategies as it could be used
to induce selective maturation of blood-derived DC,
which might lower the risk of triggering autoimmune dis-
eases.
In this paper we have concentrated on FACS analysis of
the DC derived from tonsils, and were only able to study
the secretion of one cytokine, IL-12. As DC can secrete
many cytokines, including IL12, IL15, IL18, IL10, and
TGFβ, which can affect the type of T-lymphocyte response
induced, it would be valuable to study the effect of adju-
vants on the production of other cytokines by tonsil-
derived DC. New methods are now available to do this
with small numbers of cells, and we hope to follow up
this study accordingly. It would also be useful in future to
study the effect of T-cell activation by tonsil-derived DC in
co-culture, including analysis of supernatants and exami-
nation of T cell proliferation. We believe, that co-cultures
of tonsil derived DC with autologous T lymphocytes will
prove to be a useful model system for investigation of
immune response in peripheral tissues.
Conclusion
Tissue resident DC play a vital part in systemic immune
responses, and their reaction to treatment must be takenPage 9 of 12
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cells in tissues, lymph nodes, tumours and sites of inflam-
mation are not a homogenous population but contain
myeloid and plasmacytoid DC subsets at various stages of
maturation [35-39]. Dendritic cells in tissue can migrate
to lymph nodes to orchestrate systemic immune
responses. They have contact with local infections, aller-
gens or tumours, and can be profoundly modulated by
the local environment [40,41]. We have shown, that
responses of mixed tonsil DC can be different to those of
monocultures of blood derived DC, commonly used as a
model in antigen presentation and cancer vaccine studies.
However technically complex, extended studies on the
biology of tissue resident DC, the mechanisms of interac-
tion with T lymphocytes and molecular pathways
involved in DC activation might be of considerable
importance for the management of many diseases, includ-
ing cancer, where they are a source of local tolerance and




Fifteen fresh tonsils were obtained after tonsillectomy per-
formed for recurrent tonsillitis. Informed written consent
was obtained from each patient (or a parent/guardian
when necessary) prior to surgery, in accordance with
approval by the Portsmouth and South East Hampshire
Health Authority Research Ethics Committee. Human
buffy coats were obtained from the National Blood Trans-
fusion Service, Colindale, London
Isolation of DC
Tonsils were chopped finely in a Petri dish, resuspended
in wash medium (RPMI +1 % L-glutamine + 2% Pen/
Strep + 1% Gentamycin; Sigma, Dorset, UK), and ground
through a mesh 60 tissue grinder kit (Sigma, Dorset, UK)
and then through a mesh 200 tissue grinder kit (Sigma,
Dorset, UK) to obtain a single cell suspension. Isolated
cells were washed twice and separated by density centrifu-
gation on a Ficoll gradient (Histopaque-1077, Sigma,
Dorset, UK), spun at 600 G for 30 min in bench top cen-
trifuge. Cells from the Ficoll – medium interface were col-
lected as a tonsil-derived mononuclear cell fraction, and
washed twice to remove any high density medium. The
mononuclear cells were resuspended at 2 × 108/ml in
Optiprep density gradient medium (Optiprep: Axis-
Shield, Norway), made up as a working solution 1:4.2
with wash medium and overlaid with FBS. Cells were
spun at 600 G for 15 min, and cells from the medium-FBS
interface collected as a B-lymphocyte rich APC fraction.
Cell depletion using microbeads was used to remove con-
taminating CD19+ B and CD3 positive T lymphocytes.
(Miltenyi Biotec, Bisley, UK), accordingly to the manufac-
turer's protocol. Briefly, the cell pellet was resuspended in
100 μl of MACS staining buffer (PBS + 1% BSA + 0.2 mM
EDTA; Sigma, Dorset, UK degassed) and 100 μl of CD3
and CD19 conjugated beads and FcR blocking reagent
were added for each aliquot of 108 cells. Cells were incu-
bated in 4°C for 15 min, and washed in the staining
buffer. The cell suspension was loaded onto a MACS LD
column and the negative fraction collected as tonsil DC.
Generation of DC from blood monocytes
Peripheral blood mononuclear cells (PBMC) were iso-
lated by density gradient centrifugation of buffy coat
blood preparations over lymphoprep (Axis-Shield, Nor-
way). The mononuclear fraction was diluted to 2 × 106/ml
in RPMI-1640 supplemented with 10% FCS and the
monocytes allowed to adhere to plastic Petri dishes for 1
hour at 37°C. The adherent cells were removed using a
cell scraper and contaminating T lymphocytes and B lym-
phocytes removed by MACS depletion using CD3 and
CD19 microbeads respectively, as detailed above. The
purified monocytes were adjusted to 1.0 × 106/ml in RPMI
supplemented with 5% FCS, antibiotics, 2 mM L-
glutamine (all from Sigma, Dorset, UK) and containing
GM-CSF (50 ng/ml) and IL-4 (10 ng/ml; both from Pepro-
tech EC Ltd, London). The cultures were supplemented
with GM-CSF and IL-4 every second day. After five days in
culture, the non-adherent cells were recovered for use as
immature dendritic cells.
Adjuvant activation of DC
Cells were resuspended in culture buffer (RPMI + 10%
FBS +1 % L-glutamine + 2% Pen/Strep + 1% Gentamycin;
Sigma, Dorset, UK + 0.2% metronidazole) at a concentra-
tion of 2 × 106 cells/ml and 100 μl of cell suspension was
added to each well. All of the adjuvants used in the study
were pre-titrated in the laboratory and used at optimal
concentrations similar to those used by other investiga-
tors. The final concentrations used were: Poly I:C (endo-
toxin free, Sigma, Dorset, UK) 25 μg/ml; LPS (Sigma,
Dorset, UK) 20 μg/ml; anti-CD40 monoclonal antibody
(endotoxin free, a generous gift of Professor M.J. Glennie,
University of Southampton) 10 μg/ml; IFNγ (endotoxin
free, Immunkin, Boehringer Ingelheim, Berkshire, UK)
1000 U/ml. The cells plus adjuvants were cultured in 5%
CO2, at 37°C for 38–42 hrs and then collected for further
analyses.
IL12 p70 ELISpots
To assess IL12-p70 expression, tonsil DC were cultured
with adjuvants in Mabtech ELISpot plates, (Mabtech, Swe-
den) according to the manufacturer's protocol. The plates
were ethanol-pretreated and coated with monoclonal
antibody at 150 μg/ml and incubated at room tempera-
ture for 6 hrs. Adjuvants at double concentrations were
prepared in the 96 well Mabtech plates and 100 μl of cell
suspension at 4 × 105 cells/ml was added to each well. ThePage 10 of 12
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detailed above. After 38–42 hrs of culture (5% CO2,
37°C) cells were washed off with PBS, detection antibody
applied (1:1000 in PBS + 0.5% FBS, 100 μl per well) and
the plate was incubated for 1 hr at 37°C. The detection
antibody was then washed off with PBS and 100 μl of
streptavidin-conjugated horse peroxidase added to each
well. After 1 hr of incubation, at room temperature, the
plate was washed, and 100 μl of freshly-filtered ready-
made substrate added to each well. The plate was devel-
oped until the visible spots emerged or for 30 min.
Flow cytometric analysis
Cells were collected at each step of the isolation procedure
and after cultures with adjuvants. The cell concentration
was adjusted to 2 × 106 cells/ml in PBSA (PBS + 0.2% BSA
+ 0.02% NaN3; Sigma Ltd). Fc receptor binding was
blocked with 1 μg/ml of purified mouse IgG polyclonal
antibody (1.0 μg/ml; Sigma, Dorset, UK. Fluorochrome-
conjugated monoclonal antibodies were added into each
100 μl of cell suspension. To assess fraction purity, we
stained the cells with CD19-PE, CD3-PECy5, CD14-FITC,
CD123-PE, and CD11c-PECy5 (Becton Dickinson, UK).
For activation status and maturity we used HLA class I –
FITC, HLA DR-PE, CD40-FITC, CD80-FITC, CD83-FITC,
CD86-FITC, all in combination with CD11c-PECy5 and
HLA DR-PE or CD123-PE and HLA DR-PECy5 (Becton
Dickinson, UK). All antibodies were used at pre-titrated,
optimal concentrations. As a negative control we used a
cocktail of IgG's conjugated to FITC, PE and PE/CY5
(Dako, UK). Cell suspensions were incubated at room
temperature for 10 min, washed in PBSA, and fixed in 2%
formalin in PBSA. Cells were analyzed in a Becton Dickin-
son FACSCalibur flow cytometer.
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